CG Oncology Is Building A Best-In-Class Profile In NMIBC

Cretostimogene Phase III Data Look Competitive

 
• By Joseph Haas
  
CG Oncology's Phase III data look competitive in high-risk bladder cancer (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Advanced Therapies

More from Therapy Areas